Format

Send to

Choose Destination
Exp Biol Med (Maywood). 2013 May;238(5):579-87. doi: 10.1177/1535370213488483.

Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.

Author information

1
Department of Neural and Behavioral Science, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA. Isz1@psu.eu

Abstract

The opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis is a biological pathway that is present in human ovarian cancer cells and tissues. OGF, chemically termed [Met(5)]-enkephalin, is an endogenous opioid peptide that interfaces with OGFr to delay cells moving through the cell cycle by upregulation of cyclin-dependent inhibitory kinase pathways. OGF inhibitory activity is dose dependent, receptor mediated, reversible, protein and RNA dependent, but not related to apoptosis or necrosis. The OGF-OGFr axis can be targeted for treatment of human ovarian cancer by (i) administration of exogenous OGF, (ii) genetic manipulation to over-express OGFr and (iii) use of low dosages of naltrexone, an opioid antagonist, which stimulates production of OGF and OGFr for subsequent interaction following blockade of the receptor. The OGF-OGFr axis may be a feasible target for treatment of cancer of the ovary (i) in a prophylactic fashion, (ii) following cytoreduction or (iii) in conjunction with standard chemotherapy for additive effectiveness. In summary, preclinical data support the transition of these novel therapies for treatment of human ovarian cancer from the bench to bedside to provide additional targets for treatment of this devastating disease.

KEYWORDS:

DNA synthesis; OGF; OGFr; [Met5]-enkephalin; cell proliferation; naltrexone; ovarian cancer

PMID:
23856908
DOI:
10.1177/1535370213488483
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center